Solid Biosciences has entered into more than 50 deals and licensing agreements for the use of its proprietary AAV-SLB101 capsid[1]. This capsid is specifically designed for increased biodistribution to muscle tissue and reduced distribution to the liver compared to AAV9[2]. AAV-SLB101 is used in the SGT-003 therapy for the treatment of Duchenne muscular dystrophy, which has been approved for clinical trial[6]. In the INSPIRE DUCHENNE clinical trial, 23 pediatric patients were dosed and the capsid was generally well tolerated[1]. Solid Biosciences also licenses its capsid to other companies, such as Andelyn Biosciences and Armatus Bio, to expand access to this technology[1][3]. The capsid has been clinically validated and its use may enable faster and more cost-effective development of gene therapy[1].